Prelude Capital Management’s Filana Therapeutics FLNA Stock Holding History

Prelude Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,329	Closed	-$18K	–	1996
2015 Q1	$18K	Sell	1,329 -1,142	-46%	-$15.4K	﹤0.01%	1764
2014 Q4	$35K	Sell	2,471 -400	-14%	-$6.93K	0.01%	1535
2014 Q3	$79K	Buy	+2,871	New	+$87.2K	0.01%	1202

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Prelude Capital Management's FLNA Position: Q2 2015 in Review

Prelude Capital Management sold out of Filana Therapeutics (FLNA) in Q2 2015, closing a stake of 1,329 shares — an estimated $18K sold.

Prelude Capital Management first reported a position in FLNA in Q3 2014 and held it in 3 quarters. The position peaked at $79K in Q3 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q2 2015.

Prelude Capital Management reported no remaining Filana Therapeutics position as of Q2 2015 after selling out during the quarter.
Prelude Capital Management sold 1,329 Filana Therapeutics shares in Q2 2015, an estimated $18K.
Prelude Capital Management first reported a position in Filana Therapeutics in Q3 2014 and held it in 3 quarters.
Prelude Capital Management's Filana Therapeutics position peaked at $79K in Q3 2014.
66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2015.

Based on Prelude Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.